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Disseminated superficial actinic porokeratosis (DSAP) is a 
skin condition that usually shows a poor response to different 
modalities of treatment. Herein we describe 2 patients with 
DSAP on the face, each treated with 3 to 4 sessions of 
photodynamic therapy combined with laser vaporization. 
(Ann Dermatol 23(S2) S211∼S213, 2011)
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INTRODUCTION
Photodynamic therapy (PDT) is a treatment modality 
which involves the sequential administration of a photo-
sensitizer drug and light. PDT has been reported to be 
useful in treating nonmelanoma skin cancers and a variety 
of benign skin conditions. Here, we examined whether 
PDT might be effective in the treatment of disseminated 
superficial actinic porokeratosis.
CASE REPORT
Case 1
A 61-year-old woman presented with a 10-year history of 
asymptomatic lesions on the distal part of the upper limb 
and face which were slowly increasing in size and 
number. She was distressed by the appearance of the 
lesions, especially those on the face. Clinical examination 
revealed multiple, small, circular scaly lesions on the arms 
and face, each surrounded by a fine, raised hyperkeratotic 
ridge, and with a clinical appearance typical of dissemi-
nated superficial actinic porokeratosis (DSAP). 
Dermoscopic findings aided the diagnosis (Fig. 1A). Three 
sessions of topical methyl aminolevulinate (MAL)-photo-
dynamic therapy (PDT) treatment was done on the face (1 
week and 20 days apart). Cream containing 160 mg/g 
MAL (Metvix
Ⓡ, Galderma, France) was applied in an 
occlusive manner following CO2 laser ablation of the 
individual lesions (Sharplan 40C, Sharplan Lasers Inc., Tel 
Aviv, Israel) with a continuous output power of 0.7 W in 
the superpulse mode. Multiple passes of the CO2 laser 
were applied to the rim, whereas a single pass was given 
to the central area. Despite vigorous CO2 laser ablation, 
the rims remained intact in many cases (Fig. 1B). After 3 
hours of incubation, the lesions were irradiated with a 
commercial broadband red light source (Waldmann PDT 
1200L
Ⓡ, Waldmann Medizintechnik, villingen-Schwen-
ningen, Germany, wave length: 570∼730 nm, light dose 
of 37 J/cm
2 at a fluence rate of 70 mW/cm
2, Lamp-detector 
distance of 35 cm). The red light was repeatedly shined at 
3 angles (the frontal face and right and left sides of the 
face) for even coverage. CO2 laser ablation was repeatedly 
performed in lesions with visible rims before the 2nd and 
3rd MAL-PDT treatments. The patient experienced mild HS Kim, et al
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Fig. 1. Dermoscopic findings of a disseminated superficial actinic porokeratosis lesion. The peripheral rim is prominent (A), despite
vigorous CO2 laser ablation the rims remain intact (arrows) (B).
Fig. 2. Initial lesions of disseminated superficial actinic porokeratosis on the face (A), after 3 sessions of methyl aminolevulinate
(MAL)-photodynamic therapy (PDT) (B), & diffuse scaling and aggravation of the underlying melasma following MAL-PDT (C).
The pigmentation was prominent at her follow-up visit (which occurred 1 week after the MAL-PDT) and it gradually faded with
time, lasting for about a month.
burning sensations during red light illumination and post- 
inflammatory hyperpigmentation following treatment. 
Marked clinical improvement was observed with slight 
residual hyperpigmentation at a follow-up visit 6 months 
after the 3rd MAL-PDT treatment.
Case 2
A 62-year-old woman had a 7-year history of DSAP 
lesions first appearing on the lower legs and spreading to 
involve the arms and face (Fig. 2A). The lesions were 
increasing in size and she found the appearance em-
barrassing. There was no family history of the condition. 
On examination, she had multiple, small, scaly lesions 
with a raised hyperkeratotic ridge on her legs, arms and 
face. A punch biopsy taken from a representative lesion on 
the face showed a keratin-filled epidermal invagination 
with a characteristic cornoid lamella, and confirmed the 
diagnosis of DSAP. Subsequently, treatment with MAL- 
PDT was performed on the face (she was given 4 treat-
ments). The 2nd and 3rd MAL-PDT treatment was given 
after an interval of 3 weeks and a 4th MAL-PDT after 4 
months. The treatment protocol was the same as in case 1. 
A majority of the lesions disappeared after 3 sessions of 
MAL-PDT (Fig. 2B) and the 4th session was performed to Treatment of Disseminated Superficial Actinic Porokeratosis
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remove the few remaining lesions. The patient compl-
ained of diffuse scaling of the face and aggravation of the 
underlying melasma after MAL-PDT treatment (Fig. 2C). 
The pigmentation was prominent at her follow-up visit 
which was made 1 week after the 1st MAL-PDT and gra-
dually faded with time, lasting for about a month.
DISCUSSION
DSAP, a clinical variant of porokeratosis, is an inherited, 
autosomal dominant cutaneous disorder of keratinization. 
DSAP skin lesions appear predominantly on the sun 
exposed areas of the extremities with facial involvement 
in about 15% of all DSAP cases
1. Dermoscopy aids the 
diagnosis where a “white track” structure is identified at 
the periphery of the lesion with a brownish pigmentation 
in the inner side and “double white track” in some parts of 
the lesion. The single or double “white track” structure at 
the margin corresponds to the cornoid lamella and is 
characteristic of porokeratosis
2. Although different therapeutic 
options have been proposed, including cryotherapy, topical 
5-fluorouracil and tacalcitol, the therapy of DSAP is still a 
challenge, mostly because of the multiplicity of the skin 
lesions and the frequent relapse of the disease.
PDT is a relatively new treatment modality that is 
currently used for various skin cancers, actinic keratosis 
and acne. Lesions in DSAP are thought to arise from 
proliferation of localized clones of abnormal epidermal 
cells. PDT is potentially a useful treatment option for 
DSAP as it can selectively target highly active, atypical 
cells and cause destruction by the creation of toxic 
intermediates
3. So far, 3 studies have reported the use of 
PDT with red light for the treatment of DSAP with varying 
photo-sensitizers, light sources and parameters
4-6. Striking 
clinical improvement was observed in a DSAP patient 
treated with MAL and Ankilite
Ⓡ 635 nm at a fluence of 37 
J/cm
2, whereas the same treatment was not so successful 
in a group of 6 patients with DSAP. In another study, 
DSAP of the arms and legs were treated with 20% 
aminolevulinic acid (ALA) and Waldmann PDT 1200L
Ⓡ 
570∼730 nm at a fluence of 100 J/cm
2 with disappointing 
results. Based on previous reports, we considered MAL to 
be a better choice over ALA with its higher penetration 
depth, although we do not have experience with the 
counterpart agent in DSAP. Two different red light sources 
are mainly used for MAL-PDT: Ankilite (635 nm) and 
Waldman 1200 (broad band, 570∼730 nm). Since 
Waldman 1200 has a broader wavelength, a higher fluence 
is required than with Ankilite. As previously mentioned, 
common energy settings in previous studies were 37 J/cm
2 
with Ankilite and 100 J/cm
2 with Waldman 1200, and 
there has not been a study comparing the effects of a 
single light source at different energy settings. In my case, 
I chose to use Waldman 1200 at a low fluence setting 
because post-inflammatory hyperpigmentation was 
reported to be severe in a case treated with Waldman 
1200 at a setting of 100 J/cm
2. A light dose of 37 J/cm
2 
with a broadband light source resulted in an adequate 
response in our cases. A low irradiance of 70 mW/cm
2 
was used because it correlates with an increase in 
photobiological damage. It also causes less pain and 
theoretically covers a wider area. As a pretreatment 
modality, light curettage was chosen in previous studies 
whereas in our cases we pretreated the individual lesions 
with CO2 laser ablation to enhance the effects of 
MAL-PDT.
CO2 laser vaporization itself has been a treatment option 
for DSAP, but as seen in our patients, it is not sufficient by 
itself for removing the rims. We wanted to see whether 
PDT can supplement the effects of a CO2 laser. Overall, 
PDT was found to remove some of the remnant rims of 
DSAP following CO2 laser ablation, but the degree of 
improvement was not striking. Even with the addition of 
MAL-PDT to CO2 laser vaporization, multiple sessions of 
treatment were required and complications (ex. aggra-
vation of melasma, residual pigmentation) associated with 
PDT raised some concern. However, there is a need for 
further controlled studies before drawing a conclusion on 
the effects of PDT on DSAP. In the meantime, we should 
also continue searching for a better treatment option for 
patients with DSAP.
REFERENCES
1. Sawyer R, Picou KA. Facial presentation of disseminated 
superficial actinic porokeratosis. Ear Nose Throat J 1989;68: 
57-59.
2. Zaballos P, Puig S, Malvehy J. Dermoscopy of disseminated 
superficial actinic porokeratosis. Arch Dermatol 2004;140: 
1410.
3. Levitt J, Emer JJ, Emanuel PO. Treatment of porokeratosis of 
mibelli with combined use of photodynamic therapy and 
Fluorouracil cream. Arch Dermatol 2010;146:371-373.
4. Nayeemuddin FA, Wong M, Yell J, Rhodes LE. Topical 
photodynamic therapy in disseminated superficial actinic 
porokeratosis. Clin Exp Dermatol 2002;27:703-706.
5. Cavicchini S, Tourlaki A. Successful treatment of dissemi-
nated superficial actinic porokeratosis with methyl aminole-
vulinate-photodynamic therapy. J Dermatolog Treat 2006; 
17:190-191.
6. Fernández-Guarino M, Harto A, Pérez-Garcia B, Martin- 
González M, Urrutia S, Jaén P. Photodynamic therapy in 
disseminated superficial actinic porokeratosis. J Eur Acad 
Dermatol Venereol 2009;23:176-177.